QC
ALNY icon

QCM Cayman’s Alnylam Pharmaceuticals ALNY Stock Holding History

QCM Cayman’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,522
Closed -$237K – 195
2015
Q4 		$237K Buy
+2,522
New +$234K 0.2% 90
2015
Q3 		– Sell
-2,801
Closed -$336K – 228
2015
Q2 		$336K Buy
+2,801
New +$335K 0.13% 88

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

QCM Cayman's ALNY Position: Q1 2016 in Review

QCM Cayman sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2016, closing a stake of 2,522 shares — an estimated $237K sold.

QCM Cayman first reported a position in ALNY in Q2 2015 and held it in 2 quarters. The position peaked at $336K in Q2 2015. 255 funds tracked by Wall St. Rank hold ALNY as of Q1 2016.

  • QCM Cayman reported no remaining Alnylam Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • QCM Cayman sold 2,522 Alnylam Pharmaceuticals shares in Q1 2016, an estimated $237K.
  • QCM Cayman first reported a position in Alnylam Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • QCM Cayman's Alnylam Pharmaceuticals position peaked at $336K in Q2 2015.
  • 255 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2016.

Based on QCM Cayman's 13F filing for Q1 2016, filed 16 May 2016.